Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Targeting CD74 (whose over-expression enhanced proliferation and apoptosis resistance) may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical in vitro and in vivo relapsed/refractory myeloma models.”
Title: Targeting CD74 may mitigate immune-escape features and enhance BCMA CAR-T activity in preclinical models of relapsed/refractory multiple myeloma
Authors: Xinzhuo Chen, Jingjing Zhang, Hui Chen, Renhua Huang, Xiaoxiao Zhou, Huiping Wang, Hao Xiao, Qian Peng, Fan Wu, Zhimin Zhai, Zhitao Wang
You can read the Full Article in The Journal for ImmunoTherapy of Cancer.
You can find other articles featuring Robert Orlowski on OncoDaily.
